Glucagon and cyclic AMP: Time to turn the page?

Current Diabetes Reviews

Volumn 8, Issue 5, 2012, Pages 362-381

  Rodgers, Robert L ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Adipose; Cyclic AMP; Glucagon; Heart; Liver; Phosphoenolpyruvate carboxykinase; Pyruvate kinase

Indexed keywords

ADENYLATE CYCLASE; CALCIUM; CYCLIC AMP; DIACYLGLYCEROL; G PROTEIN COUPLED RECEPTOR; GLUCAGON; GLUCOSE; INOSITOL TRISPHOSPHATE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PHOSPHOLIPASE C; PYRUVATE KINASE;

ADIPOSE TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; DIABETES MELLITUS; ENZYME ACTIVATION; GLUCONEOGENESIS; HEART; HEART MUSCLE CONTRACTILITY; HUMAN; LIPOLYSIS; LIVER; METABOLIC ACTIVATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ADIPOSE TISSUE; BIOLOGICAL TRANSPORT; CYCLIC AMP; FEMALE; GLUCAGON; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MYOCARDIUM; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); PYRUVATE KINASE; SIGNAL TRANSDUCTION;

EID: 84866656158     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339912802083540     Document Type: Article

References (266)

1. Burcelin R, Katz EB, Charron MJ. Molecular and cellular aspectsof the glucagon receptor: role in diabetes and metabolism. DiabetesMetab (Paris) 1996; 22: 373-96.
2. Brubaker PL, Drucker DJ. Structure-function of the glucagon receptorfamily of G protein-coupled receptors: The glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels 2002; 8: 179-88.
3. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol 2003; 284: E671-8.
4. Rall T, Sutherland EW, Berthet J. The relationship of epinephrineand glucagon to liver phosphorylase. IV. Effect of epinephrine andglucagon on the reactivation of phosphorylase in liver homogenates. J Biol Chem 1957; 224: 463-75.
5. Schechter Y. Evaluation of adenosine or related nucleosides asphysiological regulators of lipolysis in adipose tissue. Endocrinol1982; 110: 1579-83.
6. Sutherland EW, Rall TW. Fractionation and characterization of acyclic adenine ribonucleotide formed by tissue particles. J BiolChem 1958; 232: 1077-91.
7. Sutherland EW, Rall TW, Menon T. Adenyl cylase I. Distribution, preparation, and properties. J Biol Chem 1962; 237: 1220-27.
8. Sutherland EW. Studies on the mechanism of hormone action. Science 1972; 177: 401-08.
9. Patel, TB, Du Z, Pierre S, Cartin L, Scholich, K. Molecular biologicalapproaches to unravel adenylyl cyclase signaling and function. Gene 2001; 269: 13-25.
10. Torres TP, Sasaki N, Donahue EP, Lacy B, Printz RL, CherringtonAD, Treadway JL, Shiota M. Impact of glycogen phosphorylaseinhibitor and metformin on basal and glucagon-stimulated hepaticglucose flux in conscious dogs. J Pharmacol Exper Ther 2011; 337:610-620.
11. Epstein SE, Skelton CL, Levey GS, Entman M. Adenylyl cyclaseand cardiac contractility. Ann Intern Med 1970; 72: 561-78.
12. Birnbaumer L, Rodbell M. Adenyl cyclase in fat cells II. Hormonereceptors. J Biol Chem 1969; 244: 3477-3482.
13. Sonne O, Gliemann J. Receptor binding of glucagon and adenosine3',5'-monophosphate accumulation in isolated rat fat cells. BiochimBiophys Acta 1977; 499: 259-72.
14. Livingston JN, Cuatrecasas P, Lockwood DH. Studies of glucagonresistance in large rat adipocytes: 125I-labeledglucagon binding andlipolytic activity. J Lipid Res 1974; 15: 26-32.
15. Rodgers R, MacLeod KM, McNeill JH. Responses of rat andguinea pig hearts to glucagon. Lack of evidence for a dissociationbetween changes in myocardial cyclic 3,5-adenosine monophosphateand contractility. Circ Res 1981; 49: 216-25.
16. Exton JH, Lewis SB, Ho RJ, Robison GA, Park CR. The role ofcyclic AMP in the interaction of glucagon and insulin in the controlof liver metabolism. Ann NY Acad Sci 1971; 185: 85-100.
17. Kilts JD, Gerhardt MA, Richardson MD, Sreeram G, Mackensen B, Grocott HP, White WD, Davis RD, Newman MF, Reves JG, Schwinn DA, Kwatra MM. β-2 Adrenergic and several other Gproteinreceptors in human atrial membranes activate both Gs andGi. Circ Res 2000; 87: 707-9.
18. Laville M, Khalfallah Y, Vidal H, Beylot M, Comte B, Riou JP. Hormonal control of glucose production and pyruvate kinase activityin isolated rat liver cells: influence of hypothyroidism. Mol CellEndocrinol 1987; 50: 247-53.
19. Sánchez-Gutiérrez JC, Sánchez-Arias JA, Samper B, Felíu JE. Modulation of gluconeogenesis by epinephrine in hepatocytes isolatedfrom genetically obese (fa/fa) Zucker rats. Arch BiochemBiophys 2000; 373: 249-54.
20. Pilkis SJ, Claus TH, El-Maghrabi MR. The role of cyclic AMP inrapid and long-term regulation of gluconeogenesis and glycolysis. Adv Sec Mess Phosphoprot Res 1988; 22: 175-91.
21. Pilkis SJ, Granner DK. Molecular physiology of the regulation ofhepatic gluconeogenesis and glycolysis. Ann Rev Physiol 1992; 54:885-909.
22. Klover PJ, Mooney RA. Hepatocytes: Critical for glucose homeostasis. Int J Biochem Cell Biol 2004; 36: 753-58.
23. Jean-Baptiste E, Rizack MA, Epand RM. Lipolytic and adenylatecyclase-stimulating activity of N trinitrophenyl glucagon: comparisonwith other glucagon derivatives modified at the amino terminus. Biosci Rep 2: 1982; 163-67.
24. Livingston J, Einarsson K, Backman L, Ewerth S, Arner P. Glucagonreceptor of human liver. Studies of its molecular weight andbinding properties, and its ability to activate hepatic adenylyl cyclaseof non-obese and obese subjects. J Clin Invest 1985; 75: 397-403.
25. García-Sáinz JA, Sánchez-Sevilla L, Pelton JT, Trivedi D, HrubyDJ. Effects of [1-Nα-trinitrophenylhistidine, 12-homoarginine] glucagonon cyclic AMP levels and free fatty acid release in isolatedrat adipocytes. Biochim Biophys Acta 1986; 886: 310-16.
26. Sato N, Irie M, Kajinuma H, Suzuki K. Decreased glucagon bindingand glucagon-stimulated lipolysis in adipocytes from streptozotocin-diabetic rats. Acta Endocrinol 1989; 121: 705-13.
27. Watanabe K, Irie M, Kajinuma H, Suzuki K. Adrenalectomyinducedalterations in glucagon binding and glycolysis in isolatedrat adipocytes. Horm Metab Res 1990; 22: 215-20.
28. Lefebvre PJ. Glucagon and adipose tissue. Biochem Pharmacol1975; 24: 1261-66.
29. Rodbell M. Signal transduction: evolution of an idea. Biosci Rep1995; 15: 117-33.
30. Meier JM, McGarry JD, Faloona GR, Unger RH. Studies of thedevelopment of diabetic ketosis in the rat. J Lipid Res 1972; 13:228-33.
31. Balks HJ, Jungermann K. Regulation of peripheral insulin/glucagonlevels by rat liver. Eur J Biochem 1984; 141: 645-50.
32. Mayor P, Calle C. Glucagon binding and lipolytic response in isolatedadipocytes from streptozotocin-diabetic rats. Endocrinol Japon1988; 35: 207-15.
33. Gerich JE. Control of glycemia. In: Baillièr's Clinical Endocrinologyand Metabolism. Baillièr Tindall, Berlin. 1993; Vol. 7, 551-87.
34. Powell AM, Sherwin RS, Shulman GI. Impaired hormonal responseto hypoglycemia in spontaneously and recurrently hypoglycemicrats. J Clin Invest 1993; 92: 2667-74.
35. Inouye K, Shum K, Chan O, Mathoo J, Matthews SG, Vranic M. Effects of recurrent hyperinsulinemia with and without hypoglycemiaon counterregulation in diabetic rats. Am J Physiol 2002; 282:E1369-79, 2002.
36. Ruiter M, LaFleur SE, van Heijningen C, van der Vliet J, KalsbeekA, Buijs RM. The daily rhythm in plasma glucagon concentrationsin the rat is modulated by the biological clock and by feeding behavior. Diabetes 2003; 52: 1709-15.
37. Omer A, Duvivier-Kali VF, Aschenbach W, Tchipashvili V, GoodyearLJ, Weir GC. Exercise induces hypoglycemia in rats with islettransplantation. Diabetes 2004; 53: 360-65.
38. Sandoval D, Ping L, Neill RA, Morrey S, Davis SN. The effects ofdehydroepiandrosterone sulfate on counterregulatory responses duringrepeated hypoglycemia in conscious normal rats. Diabetes2004; 53: 679-86.
39. Charbonneau A, Melancon A, Lavoie C, Lavoie J-M. Alterations inhepatic glucagon receptor density and in Gs α and Gi α2 proteincontent with diet-induced hepatic steatosis: effects of acute exercise. Am J Physiol 2005; 289: E8-14.
40. Marliss E, Aoki TT, Unger RH, Soeldner JS, Cahill GF Jr. Glucagonlevels and metabolic effects in fasting man. J Clin Invest 1970;49: 2256-70.
41. Findlay DM, Omond S, Alford FP, Chisholm DJ. Hyperglycemiaand glucagon suppression: Possible importance of the vagus andenteric humoral factors. J Clin Endocrinol Metab 1979; 48: 13-16.
42. Jaspan J, Ruddick J, Rayfield E. Transhepatic glucagon gradients inman: evidence for glucagon extraction by human liver. J Clin EndocrinolMetab 1984; 58: 287-92.
43. Bolli GB, Tsalikian E, Haymond MW, Cryer PE, Gerich JE. Defectiveglucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. J Clin Invest 1984; 73: 1532-41.
44. Stumvoll M, Meyer C, Kreider M, Perriello G, Gerich J. Effects ofglucagon on renal and hepatic glutamine gluconeogenesis in normalpostabsorptive humans. Metabolism 1998; 47: 1227-32.
45. Evans M, Hopkins D, Macdonald IA, Amiel SA. Alanine infusionduring hypoglycaemia partly supports cognitive performance inhealthy human subjects. Diabet Med 2004; 21: 440-46.
46. Gosmanov NR, Szoke E, Israelian Z, Smith T, Cryer PE, Gerich JE, Meyer C. Role of the decrement in intraislet insulin for the glucagonresponse to hypoglycemia in humans. Diabetes Care 2005; 28:1124-31.
47. Henkel E, Menschikowski M, Koehler C, Leonhardt W, HanefeldM. Impact of glucagon response on postprandial hyperglycemia inmen with impaired glucose tolerance and type 2 diabetes mellitus. Metabolism 2005; 54: 1168-73.
48. Schwabe U, Ebert R. Different effects of lipolytic hormones andphosphodiesterase inhibitors on cyclic 3',5'-AMP levels in isolatedadipocytes. Naunyn-Schmiedeberg's Arch Pharmacol 1972; 274:287-98.
49. Honnor RC, Saggerson ED. Altered lipolytic response to glucagonand adenosine deaminase in adipocytes from starved rats. BiochemJ 1980; 188: 757-61.
50. Strassheim D, Palmer T, Milligan G, Houslay MD. Alterations inG-protein expression and the hormonal regulation of adenylate cyclasein the adipocytes of obese (fa/fa) Zucker rats. Biochem J1991; 276: 197-202.
51. Schechter Y. Evaluation of adenosine or related nucleosides asphysiological regulators of lipolysis in adipose tissue. Endocrinol1982; 110: 1579-83.
52. Mérida E, Delgado E, Molina LM, Villanueva-Peñacarillo ML, Valverde I. Presence of glucagon and glucagon-like peptide-1-(7-36) amide receptors in solubilized membranes of human adiposetissue. J Clin Endocrinol Metab 1993; 77: 1654-1657.
53. Richter WO, Schwandt P. Glycerol release from incubated humanadipocytes is not affected by gastrointestinal peptides. In J Obes1985; 9: 25-27.
54. Richter WO, Robl H, Schwandt P. Human glucagon and vasoactiveintestinal polypeptide (VIP) stimulate free fatty acid release fromhuman adipose tissue in vitro. Peptides 1989; 10: 333-35.
55. Carranza MC, Simón MA, Torres A, Romero B, Calle C. Identificationof glucagon receptors in human adipocytes from a liposarcoma. J Endocrinol Invest 1993; 16: 439-42.
56. Perea A, Clemente F, Martinell J, Villanueva-Peñacarillo ML, Valverde I. Physiological effect of glucagon in human isolated adipocytes. Horm Metab Res 1995; 27: 372-75.
57. Carlson MG, Snead WL, Campbell PJ. Regulation of free fatty acidmetabolism by glucagon. J Clin Endocrinol Metab 1993; 77: 11-15.
58. Endröczi E, Kovács Z, Lévay G, Sasváry M, Korányi L. Somatostatin-induced inhibition of lipolysis: in vitro studies. ActaPhysiol Hung 1988; 71: 77-82.
59. Giacca A, Fisher SJ, McCall RH, Shi ZQ, Vranic M. Direct andindirect effects of insulin in suppressing glucose production indepancreatized dogs: Role of glucagon. Endocrinology 1997; 138:999-1007.
60. Longuet C, Sinclair EM, Maida A, Baggio LL, Maziarz M, CharronMJ, Drucker DJ. The glucagon receptor is required for the adaptivemetabolic response to fasting. Cell Metab. 2008; 8: 359-71.
61. Lee Y, Wang M-Y, Du XQ, Charron MJ, Unger RH. Glucagonreceptor knockout prevents insulin-deficient type 1 diabetes inmice. Diabetes 2011; 60: 391-97.
62. Kreisberg R, Williamson JR. Metabolic effects of glucagon in theperfused rat heart. Am J Physiol 1964; 207: 721-27.
63. Murad F, Vaughan M. Effect of glucagon on rat heart adenyl cyclase. Biochem Pharmacol 1969; 18: 1053-59.
64. Keely SL, Corbin JD, Park CR. Regulation of adenosine 3':5'-monophosphate-dependent protein kinase. Regulation of the heartenzyme by epinephrine, glucagon, insulin, and 1-methyl-3-isobutylxanthine. J Biol Chem 1975; 250: 4832-40.
65. Henry PD, Dobson JG, Sobel BE. Dissociations between changes inmyocardial cyclic adenosine monophosphate and contractility. CircRes 1975; 36: 392-400.
66. MacLeod KM, Rodgers RL, McNeill JH. Characterization of glucagon-induced changes in rate, contractility and cyclic AMP levelsin isolated cardiac preparations of the rat and guinea pig. J PharmacolExper Ther 1981; 217: 798-804.
67. Ramachandran C, Angelos KL, Walsh DA. Cyclic AMP-dependentand cyclic AMP-independent antagonism of insulin activation ofcardiac glycogen synthase. J Biol Chem 1982; 257: 1448-57.
68. Robberecht P, Gillard M, Waelboeck M, Camus J-C, DeNeef P, Christophe J. Alterations of rat cardiac adenylate cyclase activitywith age. Eur J Pharmacol 1986; 126: 91-95.
69. Robberecht P, Damien C, Moroder L, Coy DH, Wünsch E, ChristopheJ. Receptor occupancy and adenylate cyclase activation in ratliver and heart membranes by 10 glucagon analogs modified in position2, 3, 4, 25, 27, and/or 29. Regulat Pept 1988; 21: 117-28.
70. Anand-Srivastava MB. Altered responsiveness of adenylate cyclaseto adenosine and other agents in the myocardial sarcolemma andaorta of spontaneously-hypertensive rats. Biochem Pharmacol1988; 37: 3017-22.
71. Méry P, Brechler V, Pavoine C, Pecke F. Glucagon stimulates thecardiac Ca2+ current by activation of adenylyl cyclase and inhibitionof phosphodiesterase. Nature 1990; 345: 158-61.
72. Juan-Fita MJ, Vargas ML, Hernández J. The phosphodiesterase 3inhibitor cilostamide enhances inotropic responses to glucagon butnot to dobutamine in rat ventricular myocardium. Eur J Pharmacol2005; 512: 207-13.
73. Movsesian MA. cAMP-mediated signal transduction and sarcoplasmicreticular function in heart failure. Ann NY Acad Sci 1998;853: 231-39.
74. Raju B, Cryer PE. Maintenance of the postabsorptive plasma glucoseconcentration: insulin or insulin plus glucagon? Am J PhysiolEndocrinol Metab 2005; 289: E181-86.
75. Harney JA, Rodgers RL. Insulin-like stimulation of cardiac fuelmetabolism by physiological levels of glucagon: involvement ofPI3K but not cAMP. Am J Physiol 2008; 295: E155-61.
76. Rodgers R, Christe ME, Tremblay GC, Babson JR, Daniels T. Insulin like effects of a physiologic concentration of carnitine oncardiac metabolism. Mol Cell Biochem 2001; 226: 97-105.
77. Depré C, Rider MH, Hue L. Mechanisms of control of heart glycolysis. Eur J Biochem 1998; 258: 277-90.
78. Busuttil RW, Paddock RJ, George WJ. Effects of glucagon oncardiac cyclic nucleotides in the hypoxic heart. Rec Adv Stud CardiacStruct Metab 1976; 9: 461-73.
79. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation. Ann Rev Biochem 1999; 68:965-1014.
80. Lopez-Ilasaca M, Crespo P, Pellici PG, Gutkind JS, Wetzker R. Linkage of G-protein-coupled receptors to the MAPK signalingpathway through PI 3-kinase γ. Science 1997; 275: 394-97.
81. Matsui T, Rosenzweig A. Convergent signal transduction pathwayscontrolling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J Mol Cell Cardiol 2005; 38: 63-71.
82. Curnock AP, Logan MK, Ward SG. Chemokine signalling: pivotingaround multiple phosphoinositide 3-kinases. Immunol 2002;105: 125-36.
83. Vanhaesebroeck B, Leevers SJ, Panayotu G, Waterfield MD. Phosphoinositide3-kinases: a conserved family of signal transducers. Trends Biochem Sci 1997; 22: 267-72.
84. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-7.
85. Oudit G, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascularphysiology and disease. J Mol Cell Cardiol 2004; 37:449-71.
86. GuW, Lloyd DJ, Chinookswong N, Komorowski R, Sivits Jr G, Graham M, Winters KA, Yan H, Boros LG, Lindberg RA, VéniantMM. Pharmacological targeting of glucagon and glucagon-like peptide1 receptors has different effects on energy state and glucosehomeostasis in diet-induced obese mice. J Pharmacol Exper Ther2011; 338: 70-81.
87. Pilkis SJ, Exton JH, Johnson RA, Park CR. Effects of glucagon oncyclic AMP and carbohydrate metabolism in livers from diabeticrats. Biochim Biophys Acta 1974; 343: 250-67.
88. Assimacopoulos-Jeannet FD, Blackmore PF, Exton JH. Studies onalpha-adrenergic activation of hepatic glucose output. Studies onrole of calcium in α-adrenergic activation of phosphorylase. J BiolChem 1977; 252: 2662-69.
89. Cárdenas-Tanús RJ, Huerta-Bahena J, Garcia-Sáinz JA. AngiotensinII inhibits the accumulation of cyclic AMP produced by glucagonbut not its metabolic effects. FEBS Lett 1982; 143: 1-4.
90. Clark MG, Jarrett IG. Responsiveness to glucagon by isolated rathepatocytes controlled by the redox state of the cytosolic nicotinamide-adenine dinucleotide couple acting on adenosine 3':5'-cyclicmonophosphate phosphodiesterase. Biochem J 1978; 176: 805-16.
91. Corvera S, Huerta-Bahena J, Pelton JT, Hruby VJ, Trivedi D, García-Sáinz JA. Metabolic effects and cyclic AMP levels produced byglucagon, (1-Nα-trinitrophenylhistidine12-homoarginine) glucagonand forskolin in isolated rat hepatocytes. Biochim Biophys Acta1984; 804: 434-41.
92. Exton J, Robison GA, Sutherland EW, Park CR. Studies on the roleof adenosine 3,5-monophosphate in the hepatic actions of glucagonand catecholamines. J Biol Chem 1971; 246: 6166-77.
93. Felíu JE, Hue L, Hers H-G. Hormonal control of pyruvate kinaseactivity and of gluconeogenesis in isolated hepatocytes. Proc NatAcad Sci USA 1976; 73: 2762-66.
94. Hermsdorf T, Dettmer D, Hofmann E. Age-dependent effects ofphorbol ester on adenylate cyclase stimulation by glucagon in liverof female rats. Biomed Biochim Acta 1989; 48: 255-60.
95. Ikezawa Y, Yamatani K, Ogawa A, Ohnuma H, Igarashi M, DaimonM, Manaka H, Sasaki H. Effects of glucagon on glycogenolysisand gluconeogenesis are region-specific in periportal andperivenous hepatocytes. J Lab Clin Med 1998; 132: 547-55.
96. Khan BA, Bregman MD, Nugent CA, Hruby VJ, Brendel K. (Des-Histidine1) (Nεphenylthiocarbamoyllysine)-glucagon: Effects onglycogenolysis in perfused rat liver. Biochem Biopys Res Commun1980; 93: 729-36.
97. Bizeau ME, Hazel JR. Dietary fat type alters glucose metabolism inisolated rat hepatocytes. J Nutrit Biochem 1999; 10: 709-15.
98. Wernette-Hammond ME, Lardy HA. Regulation of gluconeogenesisin hepatocytes from fasted alloxan-diabetic rats. Diabetes 1985;34: 767-73.
99. Dich J, Gluud CN. Effect of glucagon on cyclic AMP, albuminmetabolism and incorporation of 14C-leucine intp proteins in isolatedparenchymal rat liver cells. Acta Physiol Scand 1976; 97: 457-69.
100. Dighe RR, Roja FJ, Birnbaumer L, Garber AJ. Glucagon-stimulableadenylyl cyclase in rat liver. The impact of streptozotocin-induceddiabetes mellitus. J Clin Invest 1984; 73: 1013-23.
101. Marks JS, Botelho LHP. Synergistic inhibition of glucagon-inducedeffects on hepatic glucose metabolism in the presence of insulin anda cAMP antagonist. J Biol Chem 1986; 261: 15895-99.
102. Pohl SL, Birnbaumer L, Rodbell M. The glucagon-sensitive adenylcyclase system in plasma membranes of rat liver. I. Properties. JBiol Chem 1986; 246: 1849-56.
103. Srikant CB, Freeman D, McKorkle K, Unger RH. Binding andbiological activity of glucagon in liver cell membranes of chronicallyhyperglucagonemic rats. J Biol Chem 1977; 252: 7434-38.
104. Weigle DS, Koerker DJ, Goodner CJ. Pulsatile glucagon deliveryenhances glucose production by perifused rat hepatocytes. Am JPhysiol 1984; 247: E564-68.
105. Merlen C, Fabrega S, Desbuquois B, Unson CG, Authier F. Glucagon-mediated internalization of serine-phosphorylated glucagon receptorand Gsα in rat liver. FEBS Lett 2006; 580: 5697-5704.
106. Rivera N, Ramnanan CJ, An Z, Farmer T, Smith M, Farmer B, Irimia JM, Snead W, Lautz M, Roach P, Cherrington AD. Insulininducedhypoglycemia increases hepatic sensitivity to glucagon indogs. J Clin Invest 2010; 120: 4425-35.
107. Bonnevie-Nielsen V, Tager HS. Glucagon receptors on isolatedhepatocytes and hepatocyte membrane vesicles. Discrete populationswith ligand-and environment-dependent affinities. J BiolChem 1983; 258: 1313-20.
108. Andersson M, Carlquist M, Maletti M, Marie J-C. Simultaneoussolubilization of high-affinity receptors for VIP and glucagon andof a low-affinity binding protein for VIP, shown to be identical tocalmodulin. FEBS Lett 1993; 318: 35-40.
109. Wakelam M, Murphy GJ, Hruby VJ, Houslay MD. Activation oftwo signal-transduction systems in hepatocytes by glucagon. Nature1986; 323: 68-71.
110. Jelinek L, Lok S, Rosenberg GB, Smith RA, Grant FJ, Biggs S, Bensch PA, Kuijper JL, Sheppard PO, Sprecher CA, O'Hara PJ, Foster D, Walker KM, Chen LHJ, McKernan PA, Kindsvogel W. Expression cloning and signaling properties of the rat glucagon receptor. Science 1993; 259: 1614-16.
111. Altarejos JY, Montminy M. CREB and the CRTC co-activators:sensors for hormonal and metabolic signals. Nature Rev Mol CellBiol 2011; 12: 141-51.
112. Rodbell M, Birnbaumer L, Pohl SL. Characteristics of glucagonaction on the hepatic adenylate cyclase system. Biochem J 1971;125: 58P-59P.
113. Kraus-Friedmann N. Hormonal regulation of hepatic gluconeogenesis. Physiol Rev 1984; 64: 170-259.
114. Abrahamsen N, Lundgren K, Nishimura E. Regulation of glucagonreceptor mRNA in cultured primary rat hepatocytes by glucose andcAMP. J Biol Chem 1995; 270: 15853-57.
115. Beuers U, Jungermann K Relative contribution of glycogenolysisand gluconeogenesis to basal, glucagon-and nerve stimulationdependentglucose output in the perfused liver from fed and fastedrats. Biochem Int 1990; 21: 405-15.
116. Hers HG, Hue L. Gluconeogenesis and related aspects of glycolysis. Ann Rev Biochem 1983; 52: 617-53.
117. Exton JH. Mechanisms of hormonal regulation of hepatic glucosemetabolism. Diabet Metab Rev 1987; 3: 163-83.
118. Yabaluri N, Bashyam MD. Hormonal regulation of gluconeogenicgene transcription in the liver. J Biosci 2010; 35: 473-84.
119. Pilkis SJ, Claus TH. Hepatic gluconeogenesis/glycolysis: Regulationand structure/function relationships. Ann Rev Nutr 1991; 11:465-515.
120. Granner D, Andreone T, Sasaki K, Beale E. Inhibition of transcriptionof the phosphoeolpyruvate carboxykinase gene by insulin. Nature1983; 305: 549-51.
121. Fleig WE, Noether-Fleig G, Roeben H, Ditchuneit H. Hormonalregulation of key gluconeogenic enzymes and glucose release incultured hepatocytes: Effects of dexamethasone and gastrointestinalhormones on glucagon action. Arch Biochem Biophys 1984; 229:368-78.
122. Sasaki K, Cripe TP, Koch SR, Andreone TL, Petersen DD, BealeEG, Granner DK. Multihormonal regulation of phosphoenolpyruvatecarboxykinase gene transcription. The dominant role of insulin. J Biol Chem. 1984; 259: 15242-51.
123. Christ B, Nath A, Bastian H, Jungermann K. Regulation of theexpression of the phosphoenolpyruvate carboxykinase gene in culturedrat hepatocytes by glucagon and insulin. Eur J Biochem 1988;178: 373-79.
124. Christ B, Nath A, Jungermann K. Mechanism of the inhibition byinsulin of the glucagon-dependent activation of the phosphoenolpyruvatecarboxykinase gene in rat hepatocyte cultures. Action ongene transcription, mRNA level and-stability as well as hysteresiseffect. Biol Chem Hoppe-Seyler 1990; 371: 395-402.
125. Nakae J, Biggs WH 3rd, Kitamura T, Cavenee WK, Wright CV, Arden KC, Accili D. Regulation of insulin action and pancreatic β-cell function by mutated alleles of the gene encoding forkhead transcriptionfactor Fox01. Nat Genet 2002; 32: 245-53.
126. Barthel A, Schmoll D. Novel concepts in insulin regulation of hepaticgluconeogenesis. Am J Physiol 2003; 285: E685-92.
127. Dentin R, Liu Y, Koo SH, Hedrick S, Vargas T, Herediea J, Yates J3rd, Montminy M. Insulin modulates gluconeogenesis by inhibitionof the coactivator TORC2. Nature 2007; 449: 366-69.
128. Fritche L, Weigert C, Häring H-U, Lehmann R. How insulin receptorsubstrate proteins regulate the metabolic capacity of the liver-implications for health and disease. Curr Med Chem 2008; 15:1316-29.
129. Crouthamel M-C, Kahana JA, Korenchuk S, Zhang S-Y, SundaresanG, Eberwein DJ, Brown KK, Kumar R. Mechanism and managementof AKT inhibitor-induced hyperglycemia. Clin Cancer Res2009; 15: 217-25.
130. Cheng Z, White MF. Targeting forkhead box 01 from the conceptto metabolic diseases: Lessons from mouse models. Antioxid RedoxSignal 2011; 14: 649-61.
131. Chiefari E, Nevolo MT, Arcidiacono B, Maurizio E, Nocera A, Liritano S, Sgarra R, Passidente K, Palmieri C, Paonessa F, BrunettiG, Manfioletti G, Foti D, Brunetti A. HMGA1 is a noveldownstream nuclear target of the insulin receptor signaling pathway. PLoS 1 2012; 6: 1-10.
132. Iyendjian PB, Auberger P, Guigoz Y, LeCam A. Pretranslationalregulation of tyrosine aminotransferase and phosphoenolpyruvatecarboxykinase (GTP) synthesis by glucagon and dexamethasone inadult rat hepatocytes. Biochem J year 225: 77-84, 1985.
133. Hanson RW, Reshef L. Regulation of phosphoenolpyruvate carboxykinase(GTP) gene expression. Annu Rev Biochem 1997; 66:581-611.
134. Lamers WH, Hanson RW, Meisner HM. cAMP stimulates transcriptionof the gene for cytosolic phosphoenolpyruvate carboxykinasein rat liver nuclei. Proc Natl Acad Sci (USA) 1982; 79:5137-41.
135. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Mol Cell Biol 2001; 2: 599-609.
136. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, RudolphD, Schutz G, Yoon C, Puigserver P, Spiegelman B, Montminy M. CREB regulates hepatic gluconeogenesis through the coactivatorPCG-1. Nature 2001; 413: 179-83.
137. Chakravarty K, Cassuto H, Reshef L, Hanson RW. Factors thatcontrol the tissue-specific transcription of the gene for phosphoenolpyruvatecarboxykinase. Crit Rev Biochem Mol Biol 2005; 40:129-154.
138. Koo S-H, Flechner L, Qi L, Zhang X, Screaton RA, Jeffries S, Hedrick S, Xu W, Boussouar S, Brindle P, Takemori H, MontminyM. The CREB coactivator TORC2 is a key regulator of fasting glucosemetabolism. Nature 2005; 437:1109-14.
139. Canettieri G, Koo S-H, Berdeaux R, Heredia J, Hedrick S, ZhangX, Montminy M. Dual role of the coactivator TORC2 in modulatinghepatic glucose output and insulin signaling. Cell Metab 2005;2: 331-38.
140. Desvergne B, Michalik L, Wahli W. Transcriptional regulation ofmetabolism. Physiol Rev 2006; 86: 465-514.
141. Fritsche L, Weigert C, Häring H-U, Lehmann R. How insulin receptorsubstrate proteins regulate the metabolic capacity of the liver-implications for health and disease. Curr Med Chem 2008; 15:1316-29.
142. Viollet B, Guigas B, Leclerc J, Hébrard S, Lantier L, Mounier R, Andreelli F, Foretz M. AMP-activated protein kinase in the regulationof hepatic energy metabolism: from physiology to therapeuticperspectives. Acta Physiol (Oxf) 2009; 196: 81-98.
143. Gautier-Stein A, Mithieux G, Rajas F. A distal region involvinghepatocyte nuclear factor 4α and CAAT/Enhancer binding proteinmarkedly potentiates the protein kinase A stimulation of the glucose-6-phosphatase promoter. Mol Endocrinol 2005; 19: 163-74.
144. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, Rudolph D, Schutz G, Yoon C, Pulgserver P, Splegelman B, Montminy M. CREB regulates hepatic gluconeogenesis through thecoactivator PGC-1. Nature 2001; 413: 179-83.
145. Croniger CM, Millward C, Yang J, Kawai Y, Arinze IJ, Liu S, Harada-Shiba M, Chakravarty K, Friedman JE, Poli V, HansonRW. Mice with a deletion in the gene for CCAAT/Enhancerbindingprotein β have an attenuated response to cAMP and impairedcarbohydrate metabolism. J Biol Chem 2001; 276: 629-38.
146. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, AdelmantG, Stafford J, Kahn CR, Granner DK, Newgard CB, SpiegelmanBM. Control of hepatic gluconeogenesis through the transcriptionalcoactivator PGC-1. Nature 2001; 413: 131-38.
147. Koo S-H, Satoh H, Herzig S, Lee C-H, Hedrick S, Kuldarni R, Evans RM, Olefsky J, Montminy M. PGC-1 promotes insulin resistancein liver through PPAR-α-dependent induction of TRB-3. NatureMed 2004; 10: 530-34.
148. Koo S-H, Flechner L, Ling Q, Zhang X, Screaton RA, Jeffries S, Hedrick S, Xu W, Boussouar F, Brindle P, Takemori H, MontminyM. The CREB coactivator TORC2 is a key regulator of fasting glucosemetabolism. Nature 2005; 437: 1109-14.
149. Le Lay J, Tuteja G, White P, Dhir R, Ahima R, Kaestner KH. CRTC2 (TORC2) contributes to the transcriptional respons to fastingin the liver but is not required for the maintenance of glucosehomeostasis. Cell Metab 2009; 10: 55-62.
150. Raman P, Donkin SS, Spurlock ME. Regulation of hepatic glucosemetabolism by leptin in pig and rat primary hepatocytes. Am JPhysiol 2004; 286: R206-16.
151. Screaton RA, Conkright MD, Katoh Y, Best JL, Canettieri G, JeffriesS, Guzman E, Niessen S, Yates JR 3rd, Takemori H, OkamotoM, Montminy M. The CREB coactivator TORC2 functions as acalcium-and cAMP-sensitive conincindence detector. Cell 2004;119: 61-74.
152. Gerich JE, Lorenzi M, Bier DM, Tsalifian E, Schneider V, KaramJH, Forsham PH. Effects of physiological levels of glucagon andgrowth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone duringsuppression of endogenous hormone secretion with somatostatin. JClin Invest 1976; 57: 875-84.
153. Saberi M, Bjelica D, Schenk S, Imamura T, Bandyopadhyay G, LiP, Jadhar V, Vargeese C, Wang W, Bowman K, Zhang Y, PoliskyB, Olefsky JM. Novel Liver-specific TORC2 siRNA corrects hyperglycemiain rodent models of type 2 diabetes. Am J Physiol2009; 297: E1137-46.
154. Hancock AS, Du A, Liu J, Miller M, May CL. Glucagon deficiencyreduces hepatic glucose production and improves glucose tolerancein adult mice. Mol Endocrinol 2010; 24: 1605-14.
155. Liu S, Croniger C, Arizmendi C, Garada-Shiba M, Ren J, Poli V, Hanson RW, Friedman JE. Hypoglycemia and impaired hepaticglucose production in mice with a deletion of the C/EBPbeta gene. J Clin Invest 1999; 103: 207-13.
156. Spector MS, Auer K, Jarvis WD, Ishac EJN, Gao B, Kunos G, DentP. Differential regulation of the mitogen-activated protein andstress-activated protein kinase cascades by adrenergic agonists inquiescent and regenerating adult rat hepatocytes. Mol Cell Biol1997; 17: 3556-65.
157. Kimball SR, Siegfried BA, Jefferson LS. Glucagon represses signalingthrough the mammalian target of rapamycin in rat liver byactivating AMP-activated protein kinase. J Biol Chem 2004; 279:54103-09.
158. Cao W, Collins QF, Becker TC, Robidoux J, Lupo EG, Xiong Y, Daniel KW, Floering L, Collins S. p38 Mitogen-activated proteinkinase plays a stimulatory role in hepatic gluconeogenesis. J BiolChem 2005; 280: 42731-37.
159. Dalle S, Longuet C, Costes S, Broca C, Faruque O, Fontés G, HaniEH, Bataille D. Glucagon promotes cAMP-response elementbindingprotein phosphorylation via activation of ERK1/2 in MIN6cell line and isolated islets of Langerhans. J Biol Chem 2004; 279:20345-55.
160. Pei L, Waki H, Vaitheesvaran B, Wilpitz D, Kurland I, Tontonoz P. NR4A orphan nuclear receptors are transcriptional regulators of hepaticglucose metabolism. Nature Med 2006; 12: 1048-55.
161. Li XC, Carretero OA, Zhuo JL. Cross-talk between angiotensin IIand glucagon receptor signaling mediates phosphorylation of mitogen-activated protein kinases ERK 1/2 in rat glomerular mesangialcells. Biochem Pharmacol 2006; 71: 1711-19.
162. Li XC, Carretero OA, Shao Y, Zhuo JL. Glucagon receptormediatedextracellular signal-regulated kinase 1/2 phosphorylationin rat mesangial cells: role of protein kinase A and phospholipaseC. Hypertension 2006; 47: 580-85.
163. Lee J-M. Seo W-Y, Song K-H, Chanda D, Kim YD, Kim D-K, LeeM-W, Ryu D, Kim Y-H, Noh J-R, Lee C-H, Chiang JYL, Koo S-H, Choi H-S. AMPK-dependent repression of hepatic gluconeogenesisvia disruption of CREB·CRTC2 complex by orphan nuclear receptorsmall heterodimer partner. J Biol Chem 2010; 285: 32182-91.
164. Dixon M, Agius L, Yeaman SJ, Day CP. Inhibition of rat hepatocyteproliferation by transforming growth factor β and glucagon isassociated with inhibition of ERK2 and p70 S6 kinase. Hepatology1999; 29: 8-24.
165. Carling D, Mayer FW, Sanders MJ, Gamblin SJ. AMP-activatedprotein kinase: Nature's energy sensor. Nature Chem Biol 2011; 7:512-18.
166. Hayashi Y. Metabolic impact of glucagon deficiency. DiabetesObesity Metab 2011; 13 (Suppl 1): 151-157.
167. Sim AT, Hardie DG. The low activity of acetyl-CoA carboxylase inbasal and glucagon-stimulated hepatocytes is due to phosphorylationby the AMP-activated protein kinase and not cyclic AMP dependentprotein kinase. FEBS Lett 2008; 233:294-8.
168. Berglund ED, Lee-Young RS, Lustig DG, Lynes SE, Donahue EP, Camacho RC, Meredith ME, Magnuson MA, Charron MJ, WassermanDH. Hepatic energy state is regulated by glucagon receptorsignaling in mice. J Clin Invest 2009; 119: 2412-2422.
169. Berglund ED, Kang L, Lee-Young RS, Hasenour CM, Lustig DG, Lynes SE, Donahue EP, Swift LL, Charron MJ, Wasserman DH. Glucagon and lipid interactions in the regulation of hepatic AMPKsignaling and expression of PPARalpha and FGF21 transcripts invivo. Am J Physiol 2010; 299: E607-E614.
170. Valera A, Solanes G, Bosch F. Calcium-mobilizing effectors inhibitP-enolpyruvate carboxykinase gene expression in cultured rat hepatocytes. FEBS Lett. 1993; 333: 319-24.
171. Sun, P., Enslen, H., Myung, P. Maurer, R. Differential activation ofCREB by Ca2+/calmodulin-dependent protein kinase type II andtype IV involves phosphorylation of a site that negatively regulatesactivity. Genes Dev. 1994; 8: 2527-39.
172. Xiong Y, Collins QF, An J, Lupo Jr. E, Liu H-Y, Liu D, RobidouxJ, Liu Z, Cao W. p-38 mitogen-activated protein kinase plays an inhibitoryrole in hepatic lipogenesis. J Biol Chem 2007; 282: 12056-63.
173. Sterniczuk A, Hreniuk S, Scaduto RCJr, LaNoue KF. The mechanismof Ca2+-related control of glucaoneogenesis in perfused liver. Eur J Biochem 1991; 196: 143-50.
174. Claus TH, Schlumpf J, Maghrabi MR, McGrane M, Pilkis SJ. Glucagonstimulation of fructose 1,6-bisphosphatase phosphorylationin rat hepatocytes. Biochem Biophys Res Commun 1981; 100: 716-23.
175. Staddon JM, Hansford RG. Evidence indicating that glucagoninducedincrease in cytoplasmic free Ca2+concentration in hepatocytesis mediated by an increase in cyclic AMP concentration. Eur JBiochem 1989; 179: 47-52.
176. Connelly PA, Parker Botelho LH, Sisk RB, Garrison JC. A study ofthe mechanism of glucagon-induced protein phosphorylation in isolatedrat hepatocytes using (Sp)-cAMPS and (Rp)-cAMPS, thestimulatory and inhibitory diastereomers of adenosine cyclic 3'-5'-phosphorothioate. J Biol Chem 1987; 262: 4324-32.
177. Aggarwal SR, Lindros KO, Palmer TN. Glucagon stimulates phosphorylationof different peptides in isolated periportal andperivenous hepatocytes. FEBS Lett 1995; 377: 439-43.
178. Blair JB, Cimbala A, Foster JL, Morgan RA. Hepatic pyruvatekinase. Regulation by glucagon, cyclic adenosine 3':5'-monophosphate, and insulin in the perfused rat liver. J Biol Chem1976; 251: 3756-62.
179. Zanquetta MM, Nascimento EC, Mori RCT, Schaan BD, YoungME, Machado UF. Participation of β-adrenergic activity in modulationof GLUT4 expression during fasting and refeeding in rats. MetabClin Exper 2006; 55: 1538-45.
180. Hartmann H, Probst I, Jungermann K, Creutzfeldt W. Inhibition ofglycogenolysis and glycogen phosphorylase by insulin and proinsulinin rat hepatocyte cultures. Diabetes 1987; 36: 551-55.
181. Carrillo JJ, Ibares B, Esteban-Gamboa A, Felíu JE. Involvement ofboth phosphatidylinositol 3-kinase and p44/p42 mitogen-activatedprotein kinase pathways in the short-term regulation of pyruvatekinase L by insulin. Endocrinology 2001; 142: 1057-64.
182. Zhao A, Shinohara MM, Huang D, Shimizu M, Eldar-Finkelman H, Krebs EG, Beavo JA, Bornfeldt KE. Leptin induces insulin-likesignaling that antagonizes cAMP elevation by glucagon in hepatocytes. J Biol Chem 2000; 275: 11348-54.
183. Boudot C, Kadre Z, Petitfrère E, Lambert E, Chrétien S, Mayeux P, Haye B, Billat C. Phosphatidylinositol-3-kinase regulates glycosylphosphatidylinositolhydrolysis through PLC-2 activation inerythropoietin-stimulated cells. Cell. Sign. 2002; 14: 869-78.
184. Cárdenas-Tanús RJ, Huerta-Bahena J, Carcía-Sáinz JA. AngiotensinII inhibits the accumulation of cyclic AMP produced by glucagonbut not its metabolic effects. FEBS Lett 1982; 143: 1-4.
185. Murphy G, Hruby VJ, Trivedi D, Wakelam MJ, Houslay MD. Therapid desensitization of glucagon-stimulated adenylate cyclase is acyclic AMP-independent process that can be mimicked by hormoneswhich stimulate inositol phospholipid metabolism. BiochemJ 1987; 243: 39-46.
186. Unson CG, Gurzenda EM, Merrifield RB. Biological activities ofdes-His1[Glu9]glucagon amide, a glucagon antagonist. Peptides1989; 10: 1171-77.
187. Pilkis SJ, Fox E, Wolfe L, Rothbarth L, Colosia A, Stewart HB, el-Maghrabi MR. Hormonal modulation of key hepatic regulatory enzymesin the gluconeogenic/glycolytic pathway. Ann NY Acad Sci1986; 478: 1-19.
188. Blair JB, James ME, Foster JL. Adrenergic control of glycolysisand pyruvate kinase activity in hepatocytes from young and oldrats. J Biol Chem 1979; 254: 7585-90.
189. Sistare FD, Picking RA, Haynes RC Jr. Sensitivity of the responseof cytosolic calcium in quin-2-loaded rat hepatocytes to glucagon, adenine nucleosides, and adenine nucleotides. J Biol Chem 1985;260: 12744-747.
190. Connelly PA, Sisk RB, Schulman H, Garrison JC. Evidence for theactivation of the multifunctional Ca2+/calmodulin-dependent proteinkinase in response to hormones that increase intracellular Ca2+. JBiol Chem 1987; 262: 10154-63.
191. Combettes L, Berthon B, Binet A, Claret M. Glucagon and vasopressininteractions on Ca2+ movements in isolated hepatocytes. Biochem J 1986; 237: 675-83.
192. Schworer CM, EI-Maghrabi MR, Pilkis SJ, Soderling T. Phosphorylationof L-type pyruvate kinase by a Ca2+ /calmodulindependentprotein kinase. J Biol Chern 1985; 260: 3018-22.
193. Soderling TR, Schworer CM, el-Maghrabi MR, Pilkis SJ. Phosphorylationof liver phosphorylase kinase by Ca++/calmodulindependentprotein kinase: characterization of two phosphorylationsites. Biochem Biophys Res Commun 1986; 139: 1017-23.
194. Blair JB, Sattsangi S, Hartwell R. Regulation of pyruvate kinase incultured rat hepatocytes. Influence of glucose, ethanol, glucagon, and dexamethasone. J Biol Chem 1986; 261, 2425-33.
195. Felíu JE, Hue L, Hers H-G. Hormonal control of pyruvate kinaseactivity and of gluconeogenesis in isolated hepatocytes. Proc NatlAcad Sci (USA) 1976; 73: 2762-66.
196. Clark MG, Patten GS, Clark DG. Hormonal regulation of L-typepyruvate kinase in hepatocytes from phosphorylase kinase-deficient(gsd/gsd) rats. Biochem J 1984; 224: 863-69.
197. Ekdahl KN. Studies on the regulation of rat liver pyruvate kinaseand fructose-1,6-bisphosphatase. Upsala J Med Sci 1987; 92: 217-32.
198. Quentmeier A, Daneschmand H, Klein H, Unthan-Fechner K, Probst I. Insulin-mimetic actions of phorbol ester in cultured rat hepatocytes. Lack of phorbol-ester-elicited inhibition of the insulinsignal. Biochem J 1993; 289: 549-55.
199. Farese RV. Insulin-sensitive phospholipid signaling systems andglucose transport. Update II. Exp Biol Med 2001; 226: 283-95.
200. Probst I, Beuers U, Drabent B, Unthan-Fechner K, Bütkofer P. Thediacylglycerol and protein kinase C pathways are not involved ininsulin signaling in primary rat hepatocytes. Eur J Biochem 2003;270, 4635-46.
201. García-Sáinz JA, Macías-Silva M, Hernández-Sotomaor SM, Torres-Márquez ME, Trivedi D, Hruby VJ. Modulation of glucagon actionsby phorbol myristate acetate in isolated hepatocytes. Effect ofhypothyroidism. Cell Signal 1990; 2: 235-43.
202. Lenzen R, Hruby VJ, Tavoloni N. Mechanism of glucagon choleresisin guinea pigs. Am J Physiol 1990; 259: G736-44.
203. Hue L, Felíu JE, Hers H-G. Control of gluconeogenesis and ofenzymes of glycogen metabolism in isolated rat hepatocytes. BiochemJ 1978; 176: 791-97.
204. Creba JA, Downes CP, Hawkins PT, Brewster G, Michell RH, KirkCJ. Rapid breakdown of phosphatidylinositol 4-phosphateand phosphpatidylinositol 4,5-bisphosphate in rat hepatocytesstimulated by vasopressin and other Ca2+-mobilizing hormones. Biochem. J. 1983; 212: 733-47.
205. Charest R, Blackmore, PF, Berthon B, Exton JH. Changes in freecytosolic Ca2+ in hepatocytes following α1-adrenergic stimulation. Studies on quin-2-loaded hepatocytes. J Biol Chem 1983; 258:8769-73.
206. Poggioli J, Mauger J-P, Claret M. Effect of cyclic AMP-dependenthormones and Ca2+-mobilizing hormones on the Ca2+ influx andphosphoinositide metabolism in isolated rat hepatocytes. Biochem J1986; 235: 663-69.
207. Lynch CJ, Charest R, Bocckino SB, Exton JH, Blackmore PF. Inhibition of hepatic α1-adrenergic effects and binding by phorbolmyristate acetate. J Biol Chem 1985; 260: 2844-51.
208. Nishizuka Y. The molecular heterogeneity of protein kinase C andits implications for cellular regulation. Nature (Lond.) 1988; 334:661-64.
209. Garrison, J C, Borland M K, Florio VA, Twible DA. The role ofcalcium ions as a mediator of the effects of angiotensin II, catecholamines, and vasopressin on the phosphorylation and activity of enzymesin isolated hepatocytes. J Biol. Chern 1979; 254: 147-56.
210. Kubitz R, Saha N, Kühlkamp T, Dutta S, Dahl S vom, Wettstein M, Häussinger D. Ca2+-dependent protein kinase C isoforms inducecholestasis in rat liver. J Biol Chem 2004; 279: 10323-30.
211. Chen J-LJ, Babcock DF, Lardy HA. Norepinephrine, vasopressin, glucagon, and A23187 induce efflux of calcium from an exchangeablepool in isolated rat hepatocytes. Proc Nat Acad Sci USA 1978;75: 2234-38.
212. Kraus-Friedmann N. Hormonal regulation of cytosolic calciumlevels in liver. Braz J Med Biol Res 1995; 28: 275-84.
213. Aromataris EC, Roberts ML, Barritt GJ, Rychkoff GY. Glucagonactivates Ca2+ and Cl-channels in rat hepatocytes. J Physiol 2006;573: 611-25.
214. Christ B, Nath A. Impairment by interleukin 1 and tumour necrosisfactor of the glucagon-induced increase in phosphoenolpyruvatecarboxykinase gene expression and gluconeogenesis incultured hepatocytes. Biochem. J. 1996: 320; 161-66.
215. Birnbaum M, Fain JN. Activation of protein kinase and glycogenphosphorylase in isolated rat liver cells by glucagon and catecholamines. J Biol Chem 1977; 252: 528-35.
216. Birnbaumer L, Pohl SL. Relation of glucagon-specific binding sitesto glucagon-dependent stimulation of adenylyl cyclase activity inplasma membranes of rat liver. J Biol Chem 1973; 248: 2056-61.
217. Christophe J. Glucagon receptors: from genetic structure and expressionto effector coupling and biological responses. BiochimBiophys Acta 1995; 1241: 45-57.
218. Liu Y, Dentin R, Chen D, Hedrick S, Ravnskjaer K, Schenk S, Milne J, Meyers DJ, Cole P, Yates III J, Olefsky J, Guarente L, Montminy M. A fasting inducible switch modulates gluconeogenesisvia activator-coactivator exchange. Nature 2008; 456: 269-73.
219. Okajima F, Ui M. Lack of correlation between hormonal effects oncyclic AMP and glycogenolysis in rat liver. Arch Biochem Biophys1976; 175: 549-57.
220. Richards CS, Furuya E, Uyeda K. Regulation of fructose 2,6-P2concentration in isolated hepatocytes. Biochem Biophys Res Commun1981; 100: 1673-79.
221. Frank HJL, Davidson MB, Serbin PA. Insulin binding and action inisolated hepatocytes: Evidence for spare receptors. Metabolism1981; 30: 1159-64.
222. Xu Y, Xie X. Glucagon receptor mediates calcium signaling bycoupling to G alpha q/11 and G alpha i/o in HEK293 cells. J ReceptSignal Transduct Res 2009; 29: 318-25. 213.
223. Bao W, Aravindhan K, Alsaid H, Chendrimada T, Szapacs M, Citerone DR, Harpel MR, Willette RN, Lepore JJ, Jucker BM. Albiglutide, a long lasting glucagon-like peptide analog, protects therat heart against ischemia/reperfusion injury: Evidence for improvingcardiac metabolic efficiency. PLoS One. 2011; 6:e23570. Epub2011 Aug 26.
224. Hansen LH, Abrahamsen N, Nishimura E. Glucagon receptormRNA distribution in rat tissues. Peptides 1995; 16: 1163-66.
225. Watanabe M, Hayasaki H, Tamayama T, Shimada M. Histologicdistribution of insulin and glucagon receptors. Braz J Med Biol Res1998; 31: 243-56.
226. Mutel E, Gautier-Stein A, Abdul-Wahed A, Amigó-Correig M, Zitoun C, Stefanutti A, Houberdon E, Tourette J-A, Mithieux G, Rajas F. Control of blood glucose in the absence of hepatic glucoseproduction during prolonged fasting in mice. Induction of renal andintestinal gluconeogenesis by glucagon. Diabetes 2011; 60: 3121-31.
227. Meier JM, McGarry D, Faloona GR, Unger RH, Foster DW. Studiesof the development of diabetic ketosis in the rat. J Lipid Res1972; 13: 228-33.
228. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentationof hyperglucagonemia throughout the day in nonobeseand obese patients with noninsulin-dependent diabetes mellitus. JClin Endocrinol Metab 1987; 64: 106-10.
229. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack ofsuppression of glucagon contributes to postprandial hyperglycemiain subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab2000; 85: 4053-59.
230. Rizza RA. Pathogenesis of fasting and postprandial hyperglycemiain type 2 diabetes: Implications for therapy. Diabetes 2010; 59:2697-2707.
231. Raskin MD, Unger RH. Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes. N Eng J Med1978; 299: 433-36.
232. Brand CL, Jørgensen PN, Svendsen I, Holst JJ. Evidence for amajor role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes1996; 45: 1076-83.
233. Agius L. New hepatic targets for glycaemic control in diabetes. Best Pract Res Clin Endocrinol Metab 2007; 21: 587-605.
234. Dunning BE, Gerich JE. The role of alpha-cell dysregulation infasting and postprandial hyperglycemia in type-2 diabetes andtherapeutic implications. Endocrine Reviews 2007; 28: 253-83.
235. Gromada J, Duttaroy A, Rorsman P. The insulin receptor talks toglucagon? Cell Metab 2009; 9: 303-305.
236. Liang Y, Osborne MC, Monia BP, Bhanot S, Gaarde WA, Reed C, She P, Jetton TL, Demarest KT. Reduction in glucagon receptorexpression by antisense oligonucleotide ameliorates diabetic syndromein db/db mice. Diabetes 2004; 53: 410-17.
237. Sørensen H, Winzell MS, Brand CL, Fosgerau K, Gelling RW, Nishimura E, Ahren B. Glucagon receptor knockout mice displayincreased insulin sensitivity and impaired beta-cell function. Diabetes2006; 55: 3463-69.
238. Conarello S, Jiang G, Mu J, Li Z, Woods J, Zycband E, Ronan J, LiuF, Roy RS, Zhu L, Charron MJ, Zhang BB. Glucagon receptorknockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 2007;50: 142-50.
239. Mu J, Jiang G, Brady E, Dallas-Yang Q, Liu F, Woods J, ZycbandE, Wright M, Li Z, Lu K, Zhu L, Shen X, SinhaRoy R, CandeloreML, Qureshi SA, Shem D-M, Zhang F, Parmee ER, Zhang BB. Chronic treatment with a glucagon receptor antagonist lowers glucoseand moderately raises circulating glucagon and glucagon-likepeptide 1 without severe alpha cell hypertrophy in diet-inducedobese mice. Diabetologia 2011; 54: 2381-91.
240. Dobbs R, Sakurai H, Sasaki H, Faloona G, Valverde I, Baetens D, Orci L, Unger R. Glucagon: role in the hyperglycemia of diabetesmellitus. Science 1975; 187: 544-47.
241. Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi D. Hyperglycemia of diabetic rats decreased by a glucagon receptorantagonist. Science 1982; 215: 1115-16.
242. Petersen KF, Sullivan JT. Effects of a novel glucagon receptorantagonist (Bay 27-9955) on glucagon-stimulated glucose productionin humans. Diabetologia 2001; 44: 2018-24.
243. Wu C, Okar DA, Kang J, Lange AL. Reduction of hepatic glucoseproduction as a therapeutic target in the treatment of diabetes. CurrentDrug Targets 2005; 5: 51-59.
244. Estall JL, Drucker DJ. Glucagon and glucagon-like peptide receptorsas drug targets. Curr Pharm Des 2006; 12: 1731-50.
245. Kawamori D, Welters HJ, Kulkarni RN. Molecular pathways underlyingthe pathogenesis of pancreatic alpha-cell dysfunction. AdvExp Med Biol 2010; 654: 421-45.
246. Habbeger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschöp MH. The metabolic actions of glucagon revisited. Nat RevEndocrinol 2010; 6: 689-97.
247. Yan H, Gu W, Yang J, Shen Y, Lee E, Winters KA, KomorowskiR, Zhang C, Patel JJ, Caughy D, Elliott GS, Lau YY, Wang J, LiYS, Boone T, Lindberg RA, Hu S, Véniant MM. Fully humanmonoclonal antibodies antagonizing the glucagon receptor improveglucose homeostasis in mice and monkeys. J Pharmacol Exper Ther2011; 329: 102-11.
248. Miller BC, Cottam GL. Hormonal regulation of L-type pyruvatekinase in rat liver cells in culture. Arch Biochem Biophys 1987;1987; 259: 66-78.
249. Decaux J-F, Antoine B, Kahn A. regulation of the expression of theL-type pyruvate kinase gene in adult rat hepatocytes in primary culture. J Biol Chem 1989; 264: 11584-90.
250. Ichai C, Guignot L, El-Mir MY, Nogueira V, Guigas B, Chauvin C, Fontaine E, Mithieux G, Leverve XM. Glucose-6-phosphate hydrolysisis activated by glucagon in a low temperature-sensitivemanner. J Biol Chem 2001; 276: 28126-33.
251. Gauthiér-Stein A, Mithieux G, Rajas F. A distal region involvinghepatocyte nuclear factor 4α and CAAT/enhancer binding proteinmarkedly potentiates the protein kinase A stimulation of the glucose-6-phosphatase promoter. Mol Endocrinol 2005; 19: 163-74.
252. Wang Z, Iwasaki Y, Zhao LF, Nishiyama M, Taguchi T, Tsugita M, Kambayashi M, Hashimoto K, Terada Y. Hormonal regulation ofglycolytic and pyruvate dehydrogenase kinase/phosphatase genetranscription. Endocrine J 2009; 56: 1019-30.
253. Akatsuka A, Singh TJ, Nakabayashi H, Lin MC, Huyang K-P. Glucagon-stimulated phosphorylation of rat liver glycogen synthasein isolated hepatocytes. J Biol Chem 1985; 260: 3239-42.
254. Nakamura T, Kato S, Ichihara A. Glucagon and glucose as majorregulators of glycogen metabolism in primary cultured hepatocytes. J Biochem 1984; 95: 1691-96.
255. Bouscarel B, Meurer K, Decker C, Exton JH. The role of proteinkinase C in the inactivation of hepatic glycogen synthase by calcium-mobilizing agonists. Biochem J 1988; 251: 47-53.
256. García-Sáinz JA, Casas-González P. Hormonal responsiveness ofhepatocytes after hypothermic preservation in University of Wisconsinsolution. Cell Signal 1997; 9: 277-81.
257. Morgan NG, Charest R, Blackmore PF, Exton JH. Potentiation of α1-adrenergic responses in rat liver by a cAMP-dependent mechanism. Proc Nat Acad Sci USA 1984; 81: 4208-12.
258. Studer RK, Snowdowne KW, Borle AB. Regulation of hepaticglycogenolysis by glucagon in male and female rats. J Biol Chem1984; 259: 3596-3604.
259. Ekdahl KN, Ekman P. Effects of epinephrine, glucagon and insulinon the activity and degree of phosphorylation of fructose-1,6-bisphosphatase in cultured hepatocytes. Biochim Biophys Acta1987; 929: 318-26.
260. Roach PJ. Control of glycogen synthase by hierarchal protein phosphorylation. FASEB J 1990; 4: 2961-68.
261. Torres TP, Sasaki N, Donahue EP, Lacy B, Printz RL, CherringtonAD, Treadway JL, Shiota M. Impact of glycogen phosphorylase inhibitorand metformin on basal and glucagon-stimulated hepaticglucose flux in conscious dogs. J Pharmacol Exper Ther 2011; 337:610-20.
262. Pilkis SJ, El-Maghrabi MR, McGrane M, Pilkis J, Claus TH. Regulationby glucagon of hepatic pyruvate kinase, 6-phosphofructo-1-kinase, and fructose-1,6-bisphosphatase. Fed Proc 1982; 41: 2623-28.
263. Cascales M, Martin-Sanz P, Bosca L. Phorbol esters, bombesin andinsulin elicit differential responses on the 6-phosphofructo-2-kinase/fructose-2,6-isphosphatase system in primary cultures offoetal and adult rat hepatocytes. Eur J Biochem 1992; 207: 391-97.
264. Okar DA, Wu C, Lange AL. Regulation of the regulatory enzyme,6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Adv EnzRegul 2004; 44: 123-54.
265. Laville M, Khalfallah H, Vidal H, Beylot B, Comte B, Riou JP. Hormonal control of glucose production and pyruvate kinase activityin isolated rat liver cells: influence of hypothyroidism. Mol CellEndocrinol 1987; 50: 247-53.
266. Claus TH, El-Maghrabi R, Pilkis SJ. Modulation of the phosphorylationstate of rat liver pyruvate kinase by allosteric effectors andinsulin. J Biol Chem 1979; 254: 7855-64.